The U.S. Food And Drug Administration Has Declined To Approve Correvio Pharma Corp'S Drug To Correct Irregular Rhythm In The Upper Chambers Of The Heart, The Company Said On Tuesday.In The So-Called Complete Response Letter, The Fda Stated That While The Submitted Data Provides Substantial Evidence Of The Drug'S Effectiveness, The Data Does Not Provide Reassuring Evidence Of Brinavess' Safety, The Company Said.A Panel Of Independent Experts To The Fda Voted 11-2 Against Approving The Drug, Brinavess, Citing Serious Safety Risks, Including Low Blood Pressure And Irregular Rhythm In The Lower Heart Chambers During The Trials, Earlier This Month.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!